Global drug eluting balloon market is estimated to be valued at USD 713.9 Mn in 2024, and is expected to exhibit a CAGR of 8.6% during the forecast period (2024-2031). Drug eluting balloons offer an effective alternative to drug eluting stents for treating coronary artery disease by preventing the narrowing of arteries post angioplasty. These work by delivering anti-proliferative drugs like paclitaxel directly to the blood vessel walls through microscopic pores in the balloon catheter. This inhibit excessive neointimal hyperplasia and reduces the risk of restenosis. Growing geriatric population suffering from cardiovascular diseases, increasing incidences of diabetes leading to peripheral artery disease, technological advancements in drug delivery balloon catheters, and rising adoption of minimally invasive procedures  can boost demand for drug eluting balloons in the near future.

Market Dynamics:

Global drug eluting balloon market growth is driven by rising prevalence of cardiovascular diseases requiring angioplasty treatments. According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, responsible for over 17 million deaths annually. Moreover, growing elderly population that is more susceptible to arterial diseases boosts demand for drug eluting balloons. However, high costs associated with drug eluting balloons compared to plain old balloons and drug eluting stents limit their adoption in price sensitive markets. Ongoing research and development activities to develop novel drug delivery systems, biodegradable polymers, and formulate combination products offers lucrative opportunities for market players.

Key Features of the Study:

• This report provides an in-depth analysis of the global drug eluting balloon market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global drug eluting balloon market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Boston Scientific Corporation, BD, Terumo Corporation, Medtronic, B. Braun SE, Surmodics, Inc., Biotronik, Cook Medical, Opto Circuits (India) Limited, Lepu Medical Technology, Cardionovum GmbH, Shanghai MicroPort Medical (Group) Co., Ltd., Wellinq, Philips Healthcare , Biosensors International Group, Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global drug eluting balloon market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug eluting balloon market.

Detailed Segmentation-

• By Product Type:
  • Coronary Drug Eluting Balloon
  • Peripheral Drug Eluting Balloon
  • Others
• By Technology:
  • FreePac
  • TransPac
  • EnduraCoa
  • Others
• By End User:
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Company Profiles:

• Boston Scientific Corporation
• BD
• Terumo Corporation
• Medtronic
• Braun SE
• Surmodics, Inc.
• Biotronik
• Cook Medical
• Opto Circuits (India) Limited
• Lepu Medical Technology
• Cardionovum GmbH
• Shanghai MicroPort Medical (Group) Co., Ltd.
• Wellinq
• Philips Healthcare 
• Biosensors International Group, Ltd.